Tango Therapeutics, Inc.
TNGX · Price history
Price at last available close
$22.59
−$1.71 (-7.05%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Tango Therapeutics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions.
How they make money
Tango Therapeutics is a clinical-stage biotechnology company that generates revenue primarily through collaboration agreements with pharmaceutical partners. The company receives payments for research and development activities, milestone achievements, and license fees related to its proprietary precision oncology drug discovery platform.
Products & services
The company is developing a pipeline of precision oncology therapies, including TNG462, TNG348, and TNG260, designed to treat cancers with specific genetic alterations.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Pharmaceutical and biotechnology companiesSource
Disclosed major customers
- Gilead Sciences, Inc.Source
Customer concentration
For the year ended December 31, 2025, 100% of the company's total revenue was derived from the Gilead collaboration.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party providers for preclinical research, clinical trial management, and the manufacturing of drug candidates; specific supplier names are not disclosed.Source
Business relationships & partnerships
- Gilead Sciences, Inc. — A strategic collaboration for the discovery and development of novel cancer therapies, which was truncated in August 2025.Source
Strengths
- Proprietary precision oncology drug discovery platformSource
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Quarterly revenue fell 100.0% versus the same quarter last year.
Check comparable business scope and currency, then separate volume, pricing and divestitures. One weaker quarter does not establish that the same decline will continue.
Diluted weighted-average shares increased 35.6% year over year.
Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
35
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
53
Fair
Financial Strength
53
Business Quality / Moat
86
Management
40
Growth Quality
27
Risk / Durability
35
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
33
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
49/100
Building Historical Record
Model Score 49/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for TNGX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving TNGX's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can TNGX fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is TNGX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for TNGX to reach sustainable profitability?
- •What future growth or profitability would be needed to justify TNGX's current valuation?
Essential Investment Snapshot
Wall Street Score
35
Opportunity Score
33
Market Cap
$3.82B
P/E Ratio
-29.0
EPS
$-0.85
52-Week High
$34.39
52-Week Low
$6.69
Beta
1.12
Analyst Target
$40.00
Shares Outstanding
116.2M
Total Revenue
$53.8M
Total Debt
$32.0M
Dividend
No current dividend
Liquidation Value / Share
$8.82
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on TNGX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary precision oncology drug discovery platform.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of future losses.
- −Dependence on third-party collaborators and clinical trial providers.
- −Diluted weighted-average shares increased 35.6% year over year.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
35
Jul 24, 2026
Change
+0.4
points
Current Score
35
Oct 1, 2026
Category Changes
TNGX increased 0.4 points because Asset improved by 4.5 points.
Positive Contributors
- + Asset improved by 4.5 points
Projected Score
Projected Score
35
Projected Change
-0.4 points
Preliminary comparable-period financial changes suggest decline of approximately 0.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$22.66
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $53.8M | $62.4M | $42.1M | $36.5M | ···· | ···· | ···· | ···· |
| Cost of Revenue | $942K | $2.3M | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Gross Profit | $52.9M | $60.1M | $42.1M | $36.5M | ···· | ···· | ···· | ···· |
| Research & Development | $134.4M | $132.2M | $143.9M | $115.2M | ···· | ···· | ···· | ···· |
| SG&A Expenses | $56.5M | $41.5M | $43.7M | $35.5M | ···· | ···· | ···· | ···· |
| Operating Expenses | $189.2M | $171.4M | $187.7M | $150.7M | ···· | ···· | ···· | ···· |
| EBITDA | -$122.3M | -$99.3M | -$127.6M | -$99.2M | ···· | ···· | ···· | ···· |
| Operating Income | -$136.3M | -$111.3M | -$145.6M | -$114.2M | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Income Before Tax | -$123.8M | -$101.6M | -$130.1M | -$101.6M | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$63K | $4K | $208K | $134K | ···· | ···· | ···· | ···· |
| Net Income | -$123.7M | -$101.6M | -$130.3M | -$101.7M | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.85 | $-0.87 | $-1.19 | $-1.08 | ···· | ···· | ···· | ···· |
| Basic Shares | 150M | 116M | 109M | 94.57M | ···· | ···· | ···· | ···· |
| Diluted Shares | 150M | 116M | 109M | 94.57M | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.37
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-8.6%
Cash Change
+779.9%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included EPS growth, cash levels, debt levels. Pressure indicators included revenue growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 100.0%. EPS increased 5.7%. Cash increased 779.9%. Total debt declined 8.6%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
2 historical records2 historical score records available.
Historical Score Chart
2 of 2 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
Alnylam Pharmaceuticals (NASDAQ:ALNY) & Tango Therapeutics (NASDAQ:TNGX) Head to Head Survey
Rumor Mill · TNGX
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial